These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20438525)

  • 1. Effectiveness of weekly percutaneous maxacalcitol injection therapy in patients with secondary hyperparathyroidism.
    Saito A; Matsumoto Y; Oyama Y; Asaka M; Yokoyama H
    Ther Apher Dial; 2010 Feb; 14(1):98-103. PubMed ID: 20438525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
    Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
    Nephron Clin Pract; 2006; 102(1):c1-7. PubMed ID: 16166800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia.
    Shiizaki K; Hatamura I; Negi S; Narukawa N; Mizobuchi M; Sakaguchi T; Ooshima A; Akizawa T
    Kidney Int; 2003 Sep; 64(3):992-1003. PubMed ID: 12911549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.
    Chen CL; Chen NC; Liang HL; Hsu CY; Chou KJ; Fang HC; Lee PT
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
    Oyama Y; Kazama JJ; Omori K; Higuchi N; Kameda S; Yamamoto S; Ito Y; Maruyama H; Narita I; Gejyo F
    Clin Exp Nephrol; 2005 Jun; 9(2):142-7. PubMed ID: 15980949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective comparison of the effects of maxacalcitol and calcitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter, randomized crossover study.
    Mochizuki T; Naganuma S; Tanaka Y; Iwamoto Y; Ishiguro C; Kawashima Y; Maekawa K; Suda A; Akiba T;
    Clin Nephrol; 2007 Jan; 67(1):12-9. PubMed ID: 17269594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients.
    Kitaoka M; Fukagawa M; Ogata E; Kurokawa K
    Kidney Int; 1994 Oct; 46(4):1110-7. PubMed ID: 7861705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism.
    Koiwa F; Kakuta T; Tanaka R; Yumita S
    Nephrol Dial Transplant; 2007 Feb; 22(2):522-8. PubMed ID: 17127701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of intravenous calcitriol on the treatment of severe hyperparathyroidism, parathyroid gland mass and bone mineral density in haemodialysis patients.
    Huraib S; Abu-Aisha H; Abed J; Al Wakeel J; Al Desouki M; Memon N
    Am J Nephrol; 1997; 17(2):118-23. PubMed ID: 9096441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
    Hayashi M; Tsuchiya Y; Itaya Y; Takenaka T; Kobayashi K; Yoshizawa M; Nakamura R; Monkawa T; Ichihara A
    Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Suitable examination intervals for hemodialysis patients with secondary hyperparathyroidism treated with maxacalcitol].
    Yamada Y; Kumafuji M; Sodeyama T; Suzawa T; Momose M; Tokoo M
    Clin Calcium; 2005 Sep; 15 Suppl 1():144-7. PubMed ID: 16272647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].
    Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G
    Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605
    [No Abstract]   [Full Text] [Related]  

  • 13. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients.
    Fukagawa M; Kitaoka M; Yi H; Fukuda N; Matsumoto T; Ogata E; Kurokawa K
    Nephron; 1994; 68(2):221-8. PubMed ID: 7830860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Percutaneous ethanol injections in the treatment of secondary hyperparathyroidism].
    Kuzdak K; Rybińska A; Białas M
    Endokrynol Pol; 2005; 56(6):891-6. PubMed ID: 16821207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of parathyroid hormone secretion in CAPD patients by intraperitoneal administration of Maxacalcitol.
    Murakami K; Miyachi H; Watanabe A; Kawamura N; Fujii M; Koide S; Murase M; Kushimoto H; Hasegawa M; Tomita M; Hiki Y; Sugiyama S
    Clin Exp Nephrol; 2004 Jun; 8(2):134-8. PubMed ID: 15235930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the effect of intravenous calcitriol on parathyroid gland activity using double-phase technetium Tc 99m-sestamibi scintigraphy.
    Torregrosa JV; Fuster D; Ybarra J; Ortín J; Moreno A; Valveny N
    Am J Kidney Dis; 2004 Sep; 44(3):476-80. PubMed ID: 15332220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism?
    Tominaga Y; Inaguma D; Matsuoka S; Tahara H; Kukita K; Kurihara S; Onoda N; Tsuruta Y; Tsutsui S; Ohta K; Kuwahara M; Tanaka M; Nishizawa Y;
    Ther Apher Dial; 2006 Apr; 10(2):198-204. PubMed ID: 16684224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term (3 years) prognosis of parathyroid function in chronic dialysis patients after percutaneous ethanol injection therapy guided by colour Doppler ultrasonography.
    Tanaka R; Kakuta T; Fujisaki T; Tanaka S; Sakai H; Kurokawa K; Saito A
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii58-61. PubMed ID: 12771303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of percutaneous ethanol injection therapy for secondary hyperparathyroidism in patients on hemodialysis as evaluated by parathyroid hormone levels according to K/DOQI guidelines.
    Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):48-52. PubMed ID: 15828906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical verification of percutaneous maxacalcitol injection therapy on enlarged parathyroid glands in chronic dialysis patients.
    Yamamoto H; Katoh N; Takeyama H; Ikeda M; Yokoyama K; Shigematsu T; Kawaguchi Y; Hosoya T
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii50-2. PubMed ID: 12771301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.